Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922257 · ClinicalTrials.gov registry record
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
A clinical trial, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- 26
- Enrollment target
NCT02922257 is a clinical trial that has completed, run by Corcept Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT02922257 has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 \[PTX-3\], serum/glucocorticoid regulated kinase 1 \[SGK1\], and glycogen synthase kinase 3 beta \[GSK3b\]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical treatment, and detection of relapse of endogenous Cushing's syndrome after surgery.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-10-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02922257
The ClinicalTrials.gov registry entry for NCT02922257 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02922257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02922257 about?
NCT02922257 is a clinical study titled "Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery". This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 \[PTX-3\], serum/glucocorticoid regulated kinase 1 \[SGK1\], and glycogen synthase kinase 3 beta \[GSK3b\]) to be developed as a biomarker for use in diagnosis of...
What is the current status of trial NCT02922257?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2016-11. Estimated completion is 2018-10-30.
Who is sponsoring clinical trial NCT02922257?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.